A clinical study For bleeding prevention treatment with FVIIa/FX in patients with acquired hemophilia A

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1041240142

Enrollment

Registered

2024-12-12

Start date

2025-10-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

aquirwed hemophilia A

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients over 20 years old diagnosed with acquired hemophilia A (regardless of gender) 2)Patients who have bleeding tendency and have undergone bleeding treatment with bypass hemostatic products (rFVIIa, aPCC, FVIIa/FX) 3)Patients scheduled to undergo bleeding prevention treatment with emicizumab or FVIIa/FX 4)Patients who have given consent to this study from themselves or their representative

Exclusion criteria

Exclusion criteria: 1)Patients with bleeding disorders other than acquired hemophilia A 2)Patients not using bypass hemostatic products 3)Patients judged by the research director or co-investigator to be inappropriate for research participation

Design outcomes

Primary

Measure	Time frame
Number of bleedings that required treatment during the period of bleeding prevention treatment (annual blood rate)	—

Secondary

Measure	Time frame
1)Remission rate and period until remission 2) Changes in clinical test values 3) Activities of daily living (ADL) of research subjects: Changes in Bersal index (BI) 4)Serious adverse events (adverse event name, timing of onset, causal relationship)	—

Contacts

Public ContactNobuaki Suzuki

Nagoya University Hospital

suzukin@med.nagoya-u.ac.jp+81-52-744-2652

Outcome results